Inflectra
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background: Although Inflectra, biosimilar infliximab, has been approved by the EMA since September 2013 for all licensed…
Background In the light of scientific data, the medical and pharmaceutical community (rheumatology, gastroenterology, internal…
The criterion adopted by EMA for approving biosimilars is that these agents must be supported by a comparability exercise; at the…
Background: Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy for…
Background The first infliximab (IFX) biosimilar (CT-P13) in Europe is marketed as two brand names, Inflectra (IFT) and Remsima…
Background Biosimilars of infliximab have been recently introduced in clinical practice in inflammatory bowel disease (IBD) when…
Introduction Switching from an established biologic to a biosimilar to save costs was considered likely to be ‘inappropriate and…
WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning. • Increased risk of…
Introduction CT-P13 is the biosimilar Infliximab approved for use in Europe and it is marketed in the UK in two brand names…
455 Remicade in Europe, saw sales of the drug drop to $1.79 billion last year from $2.3 billion in the previous year. In a…